What does an Expanded Access Program mean for GIST patients?

Pharmaceutical companies may create an Expanded Access Program (sometimes called compassionate use) when a clinical trial is no longer enrolling but the medicine still shows promise.

By |2026-03-25T11:56:36-04:00March 5th, 2026|Clinical Trials, News, Newsletter|

Understanding Genomic Testing and SDH-Deficiency in Gastrointestinal Stromal Tumors (GISTs)

Understand why genetic testing is crucial for identifying and managing SDH-deficient GISTs, a rare and often hereditary tumor that requires specialized care.

By |2025-12-30T09:09:21-05:00April 10th, 2025|News, Newsletter|
Go to Top